Physician profile
Philip Ngai
NPI 1649614215
$36,743.79
in general payments reported to CMS, 2019-2025
26 companies · $4,358 in 2025
The $4,358 reported for 2025 was more than what 89% of Glaucoma Specialist providers received nationally (typical 2025 total: $608).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $452 · 2020: $4,303 · 2021: $4,031 · 2022: $9,180 · 2023: $7,309 · 2024: $7,111 · 2025: $4,358.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $10K · Consulting Fee: $4,550 · Food and Beverage: $4,093 · Travel and Lodging: $128.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,006.30 |
| Consulting Fee | $4,550.00 |
| Food and Beverage | $4,093.17 |
| Travel and Lodging | $127.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $22,781.49 | 2020-2025 | Omni Surgical System, Tearcare System, Sion Surgical Instrument |
| Ivantis, INC | $5,559.91 | 2019-2021 | |
| Glaukos Corporation | $3,109.42 | 2019-2025 | Idosetr |
| Alcon Research LLC | $1,650.00 | 2024 | |
| Alcon Vision LLC | $1,170.91 | 2020-2025 | Hydrus Microstent, Clareon, Rocklatan |
| Abbvie INC. | $729.52 | 2022-2025 | |
| Allergan, INC. | $356.13 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $198.47 | 2025 | Xdemvy |
| Aerie Pharmaceuticals, INC. | $172.35 | 2019-2021 | |
| Nova Eye, INC. | $165.91 | 2024-2025 | |
| Biotissue Holdings INC. | $149.77 | 2023 | |
| Genentech USA, INC. | $148.73 | 2023 | |
| Johnson & Johnson Surgical Vision, INC. | $124.36 | 2019-2024 | Tecnis Simplicity |
| Bausch & Lomb Americas INC. | $56.31 | 2023 | Envista Mx60 Iol, Amvisc |
| Sun Pharmaceutical Industries INC. | $54.36 | 2024-2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $51.05 | 2024-2025 | Tyrvaya |
| Rxsight INC | $49.60 | 2025 | Rxsight Contact Lens, Rxsight Injector Cartridge, Light Adjustable Lens (Lal) |
| Fusion Orthopedics USA, LLC | $38.46 | 2025 | |
| Carl Zeiss Meditec USA, INC. | $38.14 | 2024 | Lumera 700 |
| Rayner Intraocular Lenses Limited | $28.53 | 2025 | Omidria |
| Amgen INC. | $23.16 | 2024 | Tepezza |
| New World Medical,INC. | $20.76 | 2025 | Ahmed Glaucoma Valve, Streamline, Clearpath |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $19.85 | 2020 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Optos, INC. | $13.78 | 2019 | |
| Thea Pharma INC. | $13.42 | 2023 | Iyuzeh |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Ngai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.